

ITW

PATENT
Atty. Docket No. PP021454.0004

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first-class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

Oct. 17, 2007

By: *Joy M. Marshall*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	Qui-Lim Choo et al.
U.S. Application No.	10/580,050 ✓
I.A. Filing Date:	11/19/2004
Group Art Unit:	Not Assigned
Examiner:	To be assigned
For:	METHODS AND REAGENTS FOR TREATING, PREVENTING AND DIAGNOSING BUNYAVIRUS INFECTION

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.56 AND §1.97(b)(3)**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

The citations listed on the enclosed Information Disclosure Forms (Form PTO/SB/08A and PTO/SB/08B) may be material to the examination of the above-identified patent application. Therefore, Applicant submits these documents in compliance with the duty of disclosure as defined in 37 C.F.R. §1.56 and §1.97(b)(3). The Examiner is requested to make these citations of official record in the present application.

The present Information Disclosure Statement is being filed before the mailing date of the first Office action on the merits, and, therefore, no certification under 37 C.F.R. §1.97(e) or fee under 37


C.F.R. §1.17(p) is required.

One of the citations listed on the enclosed Information Disclosure Form is a U. S. patent. According to 37 C.F.R. §1.98(a)(2), copies of U. S. patents are not required to be included in Information Disclosure Statement submission.

This Information Disclosure Statement under 37 C.F.R. §1.56 and §1.97(b)(3) is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that these citations constitute prior art under 35 U.S.C. §102 or §103.

The Commissioner for Patents is hereby authorized to charge any additional fees (or credit any overpayment) associated with this communication and which may be required under 37 CFR 1.16 and 1.17 to Deposit Account No. 03-1664.

Respectfully submitted,

By: 
Marcella Lillis
Agent for Applicants
Reg. No. **36,583**

Date: October 16, 2007

NOVARTIS VACCINES AND DIAGNOSTICS, INC.
Corporate Intellectual Property Dept.
4560 Horton Street
Emeryville, CA 94608-2916
Telephone: (510) 923-5413
Facsimile: (510) 655-3542